Inovio Pharmaceuticals (INO) Intangibles (2010 - 2023)

Inovio Pharmaceuticals has reported Intangibles for 14 years, with the latest figure at $2.0 million in Q1 2023.

• Quarterly Intangibles fell 18.08% year-over-year to $2.0 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $2.0 million (down 18.08% YoY) and the FY2022 annual result came in at $2.1 million, down 18.9% from the prior year.
• Intangibles fell to $2.0 million in Q1 2023 per INO's latest filing, from $2.1 million in the prior quarter.
• Over five years, Intangibles peaked at $4.5 million in Q1 2019 and troughed at $2.0 million in Q1 2023.
• A 5-year average of $3.1 million and a median of $3.0 million in 2021 frame the typical range for Intangibles.
• The sharpest annual moves came in 2019 and 2020: Intangibles dropped 22.4% in 2019, then slipped 14.81% in 2020.
• Over 5 years, Intangibles stood at $3.7 million in 2019, then fell by 14.81% to $3.1 million in 2020, then slipped by 16.54% to $2.6 million in 2021, then declined by 18.9% to $2.1 million in 2022, then dropped by 3.85% to $2.0 million in 2023.
• According to Business Quant data, Intangibles over the past three periods registered $2.0 million, $2.1 million, and $2.2 million for Q1 2023, Q4 2022, and Q3 2022 respectively.